A telomerase peptide vaccine (UV1) combined with standard therapy achieved a median overall survival of 62 months and prostate cancer-specific survival of 84 months in men with newly diagnosed metastatic prostate cancer.
84-month cancer-specific survivalMen with newly diagnosed metastatic prostate cancer who received the UV1 telomerase peptide vaccine alongside standard therapy achieved a median cancer-specific survival of 7 years, with immune response independently predicting who benefited most.
What the researchers found
After a median follow-up of 62 months, nine of 22 patients were still alive. Six had no disease progression, two had castration-resistant disease on second-line therapy, and one had castration-refractory disease. Median time to PSA progression was 21 months, median overall survival was 62 months, and median prostate cancer-specific survival was 84 months.
Lack of immune response was an independent marker of prostate cancer death — patients who failed to mount an immune response to the vaccine had worse survival. Some patients showed unexpected late immune response surges without developing recurrence, suggesting ongoing immunological surveillance. These findings indicate clinical benefit of hTERT vaccination in a subgroup of patients.
Why it matters
Metastatic prostate cancer diagnosed at presentation carries a poor prognosis, with median survival typically around 4-5 years with standard therapy. The 62-month median overall survival and 84-month cancer-specific survival observed here are encouraging, particularly for a disease historically considered resistant to immunotherapy. The finding that immune response predicts survival provides a potential biomarker for identifying which patients benefit most from vaccination, moving toward personalized treatment strategies.
How the study worked
This was long-term clinical monitoring of a phase I/II study. Twenty-two men with high-grade (ISUP 4-5) de novo metastatic prostate cancer (lymph node and/or bone metastases) received the UV1 hTERT peptide vaccine combined with androgen deprivation therapy (ADT) and radiotherapy between January 2013 and July 2014. Immune responses were monitored before, during, and after vaccination, then every 6 months until PSA progression. MRI was performed at baseline, 6 months, 1 year, 2 years, and at progression.
What this study cannot tell us
This is a small single-arm phase I/II study with only 22 patients and no control group, making it impossible to definitively attribute the survival results to the vaccine versus the combination of ADT and radiotherapy. The standard of care for metastatic prostate cancer has evolved since the trial began in 2013. The long follow-up period introduces survivor bias — patients alive at later time points may have had inherently less aggressive disease. External validation in a randomized controlled trial is needed.
How to read the evidence
This is long-term follow-up of a small phase I/II single-arm trial with 22 patients. While the survival data are encouraging and the immune response correlation is notable, the absence of a control group, small sample size, and single-arm design mean that the vaccine's specific contribution to outcomes cannot be definitively established. The evidence supports further investigation in randomized trials.
When this study was published
Published in 2023 reporting on patients treated in 2013-2014, this study provides valuable long-term outcome data (up to 101 months of follow-up). The treatment landscape for metastatic prostate cancer has changed since the trial, making direct comparisons to current standard-of-care outcomes complex.
The bigger picture
Cancer vaccines targeting telomerase represent an elegant therapeutic strategy — telomerase is reactivated in approximately 85% of cancers but is largely silent in normal adult cells, making it an attractive tumor antigen. UV1 is one of several telomerase-targeting peptide vaccines in development. This long-term follow-up adds to growing evidence that immunotherapy can play a role in prostate cancer, a cancer type that has seen limited success with checkpoint inhibitors. The biomarker finding — that immune response independently predicts survival — supports the broader precision immunotherapy paradigm.
Questions still open
- Would a randomized trial confirm the survival benefit of adding UV1 vaccine to standard ADT and radiotherapy for metastatic prostate cancer?
- Can baseline immune markers predict which patients will develop strong vaccine responses and benefit most from hTERT vaccination?
- What caused the unexpected late immune response surges in some patients, and does this represent a durable anti-tumor immune memory?
Common questions
What is a telomerase peptide vaccine and how does it fight cancer?
Does the immune response to the vaccine actually matter for survival?
Read the original research
Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring.
International journal of cancer, 152(10), 2166-2173
Citation
Lilleby, Wolfgang; Seierstad, Therese; Inderberg, Else Marit; Hole, Knut Håkon. (2023). Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring.. International journal of cancer, 152(10), 2166-2173. https://doi.org/10.1002/ijc.34448